The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index; 64 of the 83 sources its claims cite were checked for support.
Research progress on HIV-1 structural proteins and antiviral therapies
Open accessAbstract
Human Immunodeficiency Virus (HIV), including HIV-1 and HIV-2, is a retrovirus that causes Acquired Immunodeficiency Syndrome (AIDS). HIV primarily targets the human immune system, especially CD4 + T lymphocytes, leading to progressive immune system dysfunction and rendering patients susceptible to severe opportunistic infections and malignancies. HIV-1 accounts for the majority of global HIV infections, and most structural, mechanistic, and therapeutic studies have been conducted in HIV-1 systems. The structural proteins Gag, Pol, and Env of HIV-1 play a pivotal role in the viral life cycle, making their functional mechanisms and inhibitor development key to advancing anti-AIDS drug research. This article provides a narrative review of recent advances in antiviral drug development targeting these proteins and discusses future design strategies. It offers critical insights for accelerating next-generation anti-HIV drug development and advancing global AIDS control efforts.
Overview
CoChat Summary
## TL;DR
This is a narrative review of HIV-1 structural proteins Gag, Pol, and Env, emphasizing how their functions make them key targets for antiviral drug development. It also reviews current therapies and future cure strategies, especially long-acting drugs, latency-reversal/silencing approaches, and gene-based interventions.
## Key findings
- Gag, Pol, and Env are presented as indispensable for the HIV-1 replication cycle: Gag drives assembly and budding, Pol provides protease/reverse transcriptase/integrase functions, and Env mediates cell entry via CD4 and CCR5/CXCR4 interactions.
- The review notes specific inhibitor progress: lenacapavir received FDA approval and allows subcutaneous dosing every 6 months; ibalizumab was FDA-approved in March 2018 for multidrug-resistant HIV-1; fostemsavir was approved in 2020 for heavily treatment-experienced adults with multidrug-resistant HIV-1.
- For reverse transcriptase inhibitors, the paper states that 8 NRTIs and 6 NNRTIs have been clinically approved; it also names common resistance pathways, including M184V/I, K65R, and NNRTI-associated K103N, Y181C, E138K, K101E, and L100I.
- The paper highlights long-acting regimen data: cabotegravir plus rilpivirine showed durable efficacy through 96 and 152 weeks in ATLAS-2M, and lenacapavir showed sustained antiviral activity in heavily treatment-experienced individuals with multidrug-resistant HIV-1 when combined with an optimized background regimen.
## Methods
- Narrative review of recent literature on HIV-1 structural proteins and antiviral therapies, with a focus on HIV-1 rather than HIV-2.
- No original sample, cohort, or experimental dataset is reported; the paper synthesizes published structural, mechanistic, clinical, and drug-development findings.
- The analysis is qualitative and thematic, organizing evidence by protein target (Gag, Pol, Env), inhibitor class, clinical use, resistance, and future therapeutic directions.
## Limitations
- The paper itself states it is a narrative review, so it does not present a systematic search protocol, meta-analysis, or new primary data; this limits the strength of any conclusions drawn from the paper itself.
- It explicitly notes that clinical evidence for some HIV-2 applications is limited, including ibalizumab and maraviroc in HIV-2 settings.
- Evident from the text: many claims about inhibitors, resistance, and future strategies are summarizations of prior studies rather than directly tested within this paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
42 Valid · 2 Not valid · 3 Not checked · 5 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“NNRTIs inhibit HIV-1 reverse transcriptase (RT) by binding to a specific, non-catalytic hydrophobic pocket known as the non-nucleoside inhibitor binding pocket (NNIBP). This binding site is located approximately 10 Å from the polymerase active site. The interaction induces conformational changes in RT that disrupt its enzymatic function, thereby inhibiting viral DNA synthesis (40, 45).”
§ Research progress on HIV-1 structural proteins and antiviral therapies > Research advances in molecular mechanisms and signaling pathways of HIV-1 protein inhibitors > Pol inhibitors
What the sources say
- Supportedcites [40] Cilento, 2021, Avoiding drug resistance in HIV reverse transcriptase, Chem Rev source
Section 3.2 states that NNRTIs bind a hydrophobic NNIBP about 10 Å from the polymerase active site. It explains that binding causes structural changes that perturb the primer grip, affect primer alignment, and ultimately inhibit chemical synthesis. (LLM, conf=0.94)
- Supportedcites [45] Wang, 2025, Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles, Sci Adv source
The Introduction states that NNRTIs bind an allosteric NNIBP about 10 Å from the polymerase active site, distorting the catalytic site and inhibiting reverse transcription. This supports the claimed binding location and inhibitory mechanism. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“It sequentially cleaves the Gag and Gag-Pol precursors, thereby processing them into mature, functional viral proteins (22).”
§ Research progress on HIV-1 structural proteins and antiviral therapies > Structural and functional roles of HIV-1 structural proteins > Pol protein
What the sources say
- Supportedcites [22] Harrison, 2022, Cryo-EM structure of the HIV-1 Pol polyprotein provides insights into virion maturation, Sci Adv source
The Introduction states that viral PR cleaves both Gag and Gag-Pol during maturation, yielding mature structural proteins and enzymes. The Discussion describes successive stages of PR activity and processing, supporting the sequential aspect. Page numbers are not available in our copy. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, its development was discontinued after the emergence of pre-existing CA-SP1 resistance mutations in a subset of patients during clinical trials (36).”
§ Research progress on HIV-1 structural proteins and antiviral therapies > Research advances in molecular mechanisms and signaling pathways of HIV-1 protein inhibitors > Gag inhibitors
What the sources say
- Partly supportedcites [36] Morales-Ramirez, 2018, Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial, PloS One sourceExperimental — accuracy not yet measured
The Introduction says bevirimat ceased clinical development because it lacked activity against naturally occurring Gag polymorphisms near the capsid–spacer peptide 1 cleavage site, present in approximately 50% of participants. It does not say those pre-existing variants emerged during treatment; the treatment-emergent Gag substitutions reported in the Results concern GSK3532795, not bevirimat. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Beyond its structural role, CA participates in multiple stages of the viral replication cycle, including reverse transcription (RT), cytoplasmic transport via microtubules, uncoating of the viral pre-integration complex, nuclear import, integration, and viral assembly (12, 13).”
§ Research progress on HIV-1 structural proteins and antiviral therapies > Structural and functional roles of HIV-1 structural proteins > Gag protein
What the sources say
- Partly supportedcites [12] Dharan, 2020, Nuclear pore blockade reveals that HIV-1 completes reverse transcription and uncoating in the nucleus, Nat Microbiol sourceExperimental — accuracy not yet measured
The Abstract (page not provided) describes CA-mediated nuclear import, capsid uncoating, and a functional role for assembled CA after nuclear entry; it also says CA influences integration-site selection. It discusses reverse transcription in relation to the capsid core, but does not establish every role in the list. Our copy does not substantiate CA-mediated cytoplasmic transport via microtubules or viral assembly. (LLM, conf=0.86)
- Supportedcites [13] Toccafondi, 2021, HIV-1 capsid core: A bullet to the heart of the target cell, Front Microbiol source
The Structural Bases section describes CA’s role in viral assembly, while Turning Cell Proteins Into Viral Cofactors describes capsid-core trafficking toward the nucleus via a microtubule-associated adaptor, uncoating, nuclear import, and selection of integration sites. The Nuclear Disassembly section also discusses reverse transcription within an intact or partly assembled capsid core. Together, these passages support the broad claim that CA participates in the listed stages; the supplied copy gives no page numbers. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“p6 domain contains PTAP and YPXL protein interaction motifs, which recruit the host endosomal sorting complex required for transport (ESCRT) to facilitate the budding of immature virions from the host cell (17).”
§ Research progress on HIV-1 structural proteins and antiviral therapies > Structural and functional roles of HIV-1 structural proteins > Gag protein
What the sources say
- Partly supportedcites [17] Bernacchi, 2022, Visualization of retroviral Gag-genomic RNA cellular interactions leading to genome encapsidation and viral assembly: An overview, Viruses sourceExperimental — accuracy not yet measured
Section 2 (Retroviral Gag Precursors; page unavailable) says HIV-1 Gag’s p6 domain contains late-domain motifs that recruit ESCRT machinery at budding sites and regulate budding of nascent virions. Our copy does not identify those motifs as PTAP and YPXL, so it does not support that specific part of the claim. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
17 more claims · 13 with their cited sources checked
Create a free account to see all 52 claims and to verify the 11 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Research progress on HIV-1 structural proteins and antiviral therapies > Research advances in molecular mechanisms and signaling pathways of HIV-1 protein inhibitors > Env inhibitors
“Another class is represented by fostemsavir (BMS-663068), a prodrug of the active attachment inhibitor temsavir, which binds directly to gp120 near the CD4-binding site and prevents the conformational changes required for viral attachment. Fostemsavir was approved in 2020 for heavily treatment-experienced adults with multidrug-resistant HIV-1 (38, 64).”
§ Research progress on HIV-1 structural proteins and antiviral therapies > Research advances in molecular mechanisms and signaling pathways of HIV-1 protein inhibitors > Env inhibitors
“Another class, represented by BMS analogs such as BMS-663068 (approved in 2018 for multidrug-resistant HIV-1), binds to a pocket near the CD4-binding site and blocks gp120 conformational changes required for viral attachment (38, 65, 66).”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Collectively, these advances are propelling HIV-1 gene therapy from proof-of-concept towards potential clinical translation (119).”
Cited work 10.1182/blood.2020006372 · retracted 2026-02-24 · notice 10.1182/blood.2026033814 · this paper published 2026-06-03
Citations
Cites
1 retracted
Rust, B. J., Kean, L. S., Colonna, L., Brandenstein, K. E., Poole, N. H., Obenza, W., Enstrom, M. R., Maldini, C. R., Ellis, G. I., Fennessey, C. M., et al. (2020) · Blood · doi:10.1182/blood.2020006372 · Cited by 58 · cited 1×
“Collectively, these advances are propelling HIV-1 gene therapy from proof-of-concept towards potential clinical translation (119).”
RetractedTwice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Bekker, L.-G., Das, M., Abdool Karim, Q., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407001 · Cited by 523 · cited 1×
“In these cells, the integrated provirus remains transcriptionally silent, does not produce viral proteins, and thereby evades immune detection, allowing the infected cells to persist long-term (85 – 88).”
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
Deeks, S. G., Archin, N., Cannon, P., Collins, S., Jones, R. B., de Jong, M. A. W. P., Lambotte, O., Lamplough, R., Ndung’u, T., Sugarman, J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01590-5 · Cited by 377
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
Segal-Maurer, S., DeJesus, E., Stellbrink, H.-J., Castagna, A., Richmond, G. J., Sinclair, G. I., Siripassorn, K., Ruane, P. J., Berhe, M., Wang, H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115542 · Cited by 331 · cited 2×
“Lenacapavir, a long-acting capsid inhibitor administered every 6 months, has also shown sustained antiviral activity in heavily treatment-experienced individuals with multidrug-resistant HIV-1 when combined with an optimized background regimen (75, 76).”
Self-citationTwice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Kelley, C. F., Acevedo-Quiñones, M., Agwu, A. L., Avihingsanon, A., Benson, P., Blumenthal, J., Brinson, C., Brites, C., Cahn, P., Cantos, V. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2411858 · Cited by 296 · cited 1×
“In parallel, vaccine-related approaches remain an important area of future development and are discussed further in the following section, particularly in the context of next-generation immunogen design and mRNA-based platforms (76, 125 – 127).”
Gandhi, R. T., Landovitz, R. J., Sax, P. E., Smith, D. M., Springer, S. A., Günthard, H. F., Thompson, M. A., Bedimo, R. J., Benson, C. A., Buchbinder, S. P., et al. (2025) · JAMA · doi:10.1001/jama.2024.24543 · Cited by 265 · cited 1×
“…active antiretroviral therapy, which typically combines multiple drug classes, including nucleoside reverse transcriptase inhibitors (Tenofovir, Lamivudine, Abacavir), non-nucleoside reverse transcriptase inhibitors (Rilpivirine), and integrase strand transfer inhibitors (Dolutegravir) (71, 72).”
Dharan, A., Bachmann, N., Talley, S., Zwikelmaier, V., & Campbell, E. M. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0735-8 · Cited by 223 · cited 1×
“Beyond its structural role, CA participates in multiple stages of the viral replication cycle, including reverse transcription (RT), cytoplasmic transport via microtubules, uncoating of the viral pre-integration complex, nuclear import, integration, and viral assembly (12, 13).”
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Kozal, M., Aberg, J., Pialoux, G., Cahn, P., Thompson, M., Molina, J.-M., Grinsztejn, B., Diaz, R., Castagna, A., Kumar, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1902493 · Cited by 181
Curing HIV: Seeking to Target and Clear Persistent Infection
Margolis, D. M., Archin, N. M., Cohen, M. S., Eron, J. J., Ferrari, G., Garcia, J. V., Gay, C. L., Goonetilleke, N., Joseph, S. B., Swanstrom, R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.005 · Cited by 178 · cited 1×
“Conversely, another approach is durable proviral silencing, which seeks to maintain deep latency or long-term viral silencing using epigenetic modi fi ers such as dCA, thereby maintaining the provirus in a transcriptionally inactive state and preventing future reactivation (96, 97).”
Jensen, B.-E. O., Knops, E., Cords, L., Lübke, N., Salgado, M., Busman-Sahay, K., Estes, J. D., Huyveneers, L. E. P., Perdomo-Celis, F., Wittner, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02213-x · Cited by 158
Cited by
Kumar, A. S., Sanober, M., & Mamidala, E. (2026) · Research Square · doi:10.21203/rs.3.rs-10950316/v1
Metadata
- Authors
- Wang, H., Yuan, J., & Wang, H.
- Affiliations
- First Hospital of Jilin University (CN)
- Corresponding author
- Wang, Hong
- ORCID
- Wang, Huihan
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2026-06-03
- Volume
- 17
- Pages
- 1805597-1805597
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC13272464
- OpenAlex
- W7163380950
- Semantic Scholar
- a3a446c173a0f5799280d79129cb592dee5c79ad
- Cited by
- 2
- References
- 139
- Citations by year
- 2026: 2
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- HIV-1, structural proteins, Gag, pol, Env, antiviral drug discovery, HIV-1 life cycle, CD4+ T cells, AIDS, HIV-2, drug design strategies
- MeSH terms
- Animals, Humans, HIV-1, HIV Infections, Anti-HIV Agents, gag Gene Products, Human Immunodeficiency Virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Research progress on HIV-1 structural proteins and antiviral therapies. https://app.cochat.ai/papers/10.3389/fimmu.2026.1805597
- The paper
- Wang, H., Yuan, J., & Wang, H. (2026). Research progress on HIV-1 structural proteins and antiviral therapies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1805597
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.